Novel and Emerging Therapies for Inflammatory Bowel Disease.

Front Pharmacol · 2021 · PMC8080036 · PMID 33935763

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In summary, the phase II dose ranging study of mirikizumab showed a trend toward inducing clinical remission and response around week 12 in patients with moderate-severe UC ( Sandborn et al., 2020d ).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

The rate of endoscopic response and mucosal healing in the overall filgotinib group was numerically higher but did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.